Oncotarget

Oncotarget

Spotlight

Oncotarget Further Increases Its Publication Frequency

Due to rising importance, impact, volume and quality, Oncotarget will begin publishing two issues per week on Tuesday and Friday.

To accelerate the dissemination of highly important scientific information, all accepted papers will be included directly to final paginated issues to be released to PubMed quickly and in their permanent form.

Issues 8(31-40) are now in PubMed. Please see the link.

Issues 8(41-43) are currently submitting and processing by the National Library of Medicine to appear in PubMed.

By submitting two issues per week we will cover the gap and there will be no delays in the future.

New Impact factor (IF) is 5.168

Title IF
e-Life 7.725
Oncogene 7.519
Oncotarget 5.168
Mol Cell Biol 4.398
Sci Reports 4.259
JBC 4.125
BMC Cancer 3.288
PLOS ONE 2.806

Oncotarget’s rising popularity is due to insightful, constructive, punctual, multiple peer-review: helping our authors to increase the impact of their research

Featured articles by DR Lowy, the acting director of the NCI (2015-2017):

DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers.
Wang D, Qian X, Rajaram M, Durkin ME, Lowy DR.
Oncotarget. 2016 Jul 19;7(29):45144-45157.

DLC1: a tumor suppressor that regulates Rho signaling.
Tripathi BK, Lowy DR.
Oncotarget. 2017 Apr 25;8(17):27674-27675.

2016 Collection of Priority papers

Oncotarget In The News

Oncotarget is accepting papers on topics beyond oncology: Neuroscience, Endocrinology, Cardiology, Metabolism, Cell Biology, Pharmacology (all areas) and more

Impact factor (IF) Thomson Reuters JCR

Year IF Total Cites
2016/2017 5.168 30241
2015 5.008 10452
2014 6.359 3908
2013 6.627 2217
2012 6.636 1450
2011 4.784 493

2015/2016: 5-Year Impact Factor: 5.415

Scopus/SJR ranking: 2011-ongoing: Q1 (highest rank). All years Q1 in Medicine (subject area) and Oncology

Oncotarget ranks number 1 on Total Documents (2015-2016) among all journals in Oncology, see here

If your paper was mistakenly rejected by other leading journals, you may submit it to Oncotarget together with peer-reviews obtained from the other journal and rebuttal letter.

The term "oncotarget" encompasses all molecules, pathways, and cellular functions common in cancer and aging, neurodegeneration and atherosclerosis, lymphocytes and neurons, cancer cells and microbes.

Oncotarget is a multidisciplinary traditional journal with free-access. Oncotarget publishes papers online in weekly issues. Each issue or paper can be printed for special demand.

Our mission is to make scientific results rapidly and widely available. To maximize the impact of research via insightful review. To allow exceptional discoveries to be shared quickly. To eliminate the border between specialties. To link different fields of biomedical science. To foster applications of basic and clinical science to fight disease.

Under the leadership of the most prominent scientists, the journal helps all researchers contribute to the progress of science. Life without disease is our ultimate goal.

The success of Oncotarget has prompted us to launch sections beyond oncology.

250 Plus Papers from the Editorial Board:
See full list



Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC